Life Sciences companies are rethinking how they will thrive in a world with increasing government regulation, cost efficient health plans and universal healthcare. Operational efficiency across biotechnology, pharmaceuticals, medical device manufacturers and diagnostic testing is of prime importance.
These changing market conditions will impact manufacturing, research and development, sales, marketing and distribution. As a result, improved decision making grounded in comprehensive information analysis is needed to compete effectively.
Explore results associated with patients, drugs and symptoms to identify dangerous interactions and minimize risk. Share results with other scientists and research staff. Improve your operational efficiency by analyzing cost structures, distribution effectiveness and the manufacturing process.
View screenshots
A need to go beyond the traditional sales and marketing model tied to physician based distribution.
Measure the effect of new sales and marketing campaigns designed to communicate directly with consumers.
Deeper analysis of cost structures across all operations in the business.
Integrate general ledger data with other data sources on the cost of raw materials and production to identify where efficiencies can be built into the business.
Improvements in the manufacturing and R&D for therapeutics which may take into account overseas labor production.
Improve the manufacturing and R&D process through event timeline analysis.
Identifying the most promising genes in support of developing new treatment strategies, enhanced testing and targeting specific disease states.
Identify non-obvious relationships between specific genes and links to diseases leading to new drugs and treatment therapies.
Early detection of effects tied to drug interactions that could either reduce the risk or confirm the safety of new products available for patients.
Analyze clinical trial data to determine the effects of drug interactions which could lead to detecting defects in the manufacturing process.